Immunology Investor Event
sanofi
Beyond Type 2: Opportunity for amlitelimab and
rilzabrutinib in patients with mixed inflammatory response
Upstream Initiation
Activation
Virus
Bacteria Allergens Epithelial Injury
Tissue Effects
Amplification
Atopic Dermatitis
Precision Medicine Approach
९ 2
IL-33
TSLP
IL-25
Th2
APC
OX40L OX40
Teff
IL-5
Eosinophil
IL-4
IL-13
Th2
Th17
IL-17
Th22
IL-22
B cell
xx
IgE
Th2 dominant
DupixentⓇ
amlitelimab
(anti-OX40L)
Neutrophil
Th17/22+Th2
(mixed)
DupixentⓇ
amlitelimab
(anti-OX40L)
Source: https://www.type2inflammation.com/science-cytokines. Immunity. 2019 Apr 16;50(4):778-795
Noda et al, J Al Clin Imm 2015 Nov;136(5):1254-64.
All listed agents, except Dupixent, are investigational and the safety and efficacy has not been evaluated by any regulatory authority.
30 Immunology Investor Event
rilzabrutinib
(BTKi)View entire presentation